Bisphosphonate therapy

PreclinicalSmall molecule

SState University of New York - Upstate Medical University

Bisphosphonate therapy is one of 7 small molecule programs targeting Childhood Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Childhood CancerActive, not recruiting

Childhood CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Childhood Cancer

#DrugCompanyPhaseTrials

Ritalin

Novartis

Approved

2 2

Nuvigil

NNuvo Research GmbH

Approved

—3

Mozobil

GGenzyme, a Sanofi Company

Glucophage

1 5

Opdivo

Bristol-Myers Squibb

Preclinical

—6

Naropin

FFresenius Kabi USA, LLC

Preclinical

—7

Bisphosphonate therapy

SState University of New York - Upstate Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Postmenopausal Osteoporosis1 trial

Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis

Completed·OOndokuz Mayıs University·Phase 4·NCT04149405·43 enrolled

Childhood Cancer1 trial

Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

Terminated·SState University of New York - Upstate Medical University·N/A·NCT00145704·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Bisphosphonate therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bisphosphonate therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bisphosphonate therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — State University of New York - Upstate Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SState University of New York - Upstate Medical University

Bisphosphonate therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Postmenopausal Osteoporosis1 trial

Childhood Cancer1 trial

References

Drug Info

Quick Facts

Related News